1026514-30-6

Basic information

• Product Name: 2-benzyloxycarbonylamino-3-[7-chloro-1-(diethoxy-phosphorylmethyl)-1H-benzoimidazol-2-yl]-propionic acid benzyl ester
• Synonyms: 2-benzyloxycarbonylamino-3-[7-chloro-1-(diethoxy-phosphorylmethyl)-1H-benzoimidazol-2-yl]-propionic acid benzyl ester
• CAS NO: 1026514-30-6
• Molecular Weight: 614.035
• Mol File: 1026514-30-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-benzyloxycarbonylamino-3-[7-chloro-1-(diethoxy-phosphorylmethyl)-1H-benzoimidazol-2-yl]-propionic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-benzyloxycarbonylamino-3-[7-chloro-1-(diethoxy-phosphorylmethyl)-1H-benzoimidazol-2-yl]-propionic acid benzyl ester(1026514-30-6)
• EPA Substance Registry System: 2-benzyloxycarbonylamino-3-[7-chloro-1-(diethoxy-phosphorylmethyl)-1H-benzoimidazol-2-yl]-propionic acid benzyl ester(1026514-30-6)

Safety Data

• Hazardous Substances Data: 1026514-30-6(Hazardous Substances Data)

Upstream product

• 345203-23-8 [(2-chloro-6-nitrophenylamino)methyl]phosphonic acid diethyl ester 
• 345203-24-9 [(2-amin-6-chlorophenylamino)methyl]phosphonic acid diethyl ester 
• 3209-22-1 1,2-Dichloro-3-nitrobenzene 
• 2106-49-2 1-chloro-2-fluoro-3-nitrobenzene 
• 345203-25-0 [R(-)]-2-benzyloxycarbonylamino-N-{2-chloro-6-[(diethoxy-phosphorylmethyl)-amino]-phenyl}-succinamic acid benzyl ester 

Relevant articles and documents

Design, synthesis, SAR, and biological evaluation of highly potent benzimidazole-spaced phosphono-α-amino acid competitive NMDA antagonists of the AP-6 type

A series of 2-amino-(phosphonoalkyl)-1H-benzimidazole-2-alkanoic acids was synthesized and evaluated for NMDA receptor affinity using a [3H]CPP binding assay. Functional antagonism of the NMDA receptor complex was evaluated in vitro using a stimulated [3H]TCP binding assay and in vivo by employing an NMDA-induced seizure model. Several compounds of the AP-6 type demonstrated potent and selective NMDA antagonistic activity both in vitro and in vivo. In particular, [R(-)]-2-amino-3-(5-chloro-1-phosphonomethyl-1H-benzoimidazol-2-yl)-propionic acid (1) displayed an IC50 value of 7.1 nM in the [3H]CPP binding assay and an ED50 value of 0.13 mg/kg (ip) in the NMDA lethality model. Compound 1, when administered intravenously as a single bolus dose of 3 mg/kg following permanent occlusion of the middle cerebral artery in the rat, reduced the volume of infarcted brain tissue by 45%. These results support a promising therapeutic potential for compound 1 as a neuroprotective agent.